05 Jul 2016
Industry veteran to lead growing business segment for companyPatheon, a leading global provider of pharmaceutical development and manufacturing services, announced today that Patrick Glaser was appointed senior vice president of the company’s small molecule active pharmaceutical ingredient (API) business. He will be responsible for leading the transformation and expansion of the company’s API service offering in Europe and North America and will report to Lukas Utiger, president of Patheon’s drug substance services division.Glaser joins Patheon frommore...
31 May 2016
Brings 20+ Years Global, Operational and Financial Experience to PatheonDURHAM, N.C.--(BUSINESS WIRE)--Patheon, the leading global provider of pharmaceutical development and manufacturing services announced today that Michel Lagarde has been appointed as its President, effective immediately. In this newly created role, Lagarde will lead global corporate and cross-enterprise operations and report to Patheon CEO, James Mullen. Mullen will continue to direct the company’s global growth strategy, as well as oversee the Patheon’s business segments,more...
15 Mar 2016Flexible Manufacturing Can Help Pharmaceutical Industry Avoid High Costs of Inaccurate Demand Forecasts
Survey about product launch challenges finds instances of demand forecasts off by more than 50 percent, leading to sales losses and reputation damageDURHAM, N.C.--(BUSINESS WIRE)--A survey of 50 pharmaceutical industry senior managers found a majority of companies had either overestimated or underestimated demand for new drugs by up to 25 percent, with some reporting instances of forecasts being off by more than 50 percent. The results of the survey – conducted by business intelligence firm ORC International and sponsored by Patheon, a leading global provider of high-quality drug development and delivery solutions to themore...